Trent:₹3,256.10+30.96 (+0.96%)
Reliance Industries:₹1,377.50+1.93 (+0.14%)
Adani Ports:₹1,917.00-0.19 (-0.01%)
Tata Consumer:₹1,155.90+11.90 (+1.04%)
Titan Company:₹4,620.00-79.90 (-1.70%)
TCS:₹2,376.20+33.50 (+1.43%)
Trent:₹3,256.10+30.96 (+0.96%)
Reliance Industries:₹1,377.50+1.93 (+0.14%)
Adani Ports:₹1,917.00-0.19 (-0.01%)
Tata Consumer:₹1,155.90+11.90 (+1.04%)
Titan Company:₹4,620.00-79.90 (-1.70%)
TCS:₹2,376.20+33.50 (+1.43%)
Refer & Earn
Arihant Plus App

Arihant Plus App

Anlon Healthcare Ltd

Anlon Healthcare | 544497

Market Closed
₹25.17
+₹0.20 (+0.80%)
As on 22/11/26, 11:10 PM
Market Cap1,327.19 CR
Current Price₹25.17
High / Low₹37.24 / 10.37
PE Ratio20.76
Book Value₹43.32
Dividend Yield0.00%
ROCE21.95%
ROE19.17%
Face Value₹2.00
Current Vol.48,46,543
Average Vol.---
ISININE0Y8W01025
PB Ratio2.57
Debt to Equity0.35
Net Profit Margin16.92
Operating Margin27.78

AHCL - Share Price Chart

+₹0.00 (+0.00%)6M

Stock Performance

₹24.97₹24.83
₹25.17
Previous CloseToday's Open
₹10.37₹37.24
₹25.17
52W Low52W High
₹24.83Today's Open
₹24.97Previous Close
48,46,543Volume
₹10.3752W Low
₹37.2452W High

Ratios

No data available

About Company

  • Anlon Healthcare Limited was originally incorporated as 'Anlon Ventures Private Limited', dated November 19, 2013 with the RoC
  • The Company changed the name to 'Anlon Healthcare Private Limited' dated May 27, 2015 issued by the RoC and further beame a Public Company named 'Anlon Healthcare Limited' dated September 2, 2024
  • ANLON an ideal API partner is research-driven company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Bulk Drugs and advanced pharmaceutical intermediates
  • It specialize in manufacturing of high-purity pharmaceutical intermediates used as key starting materials for APIs and finished dosage formulations
  • It is among the few Indian manufacturers of products such as Loxoprofen Sodium Dihydrate, Ketoprofen, and Dexketoprofen Trometamol, which are widely used in pain management and anti-inflammatory therapies which comply with the regulatory requirements of leading health authorities such as FDA, PMDA, KFDA, cGMP, WHO-GMP
  • In addition to manufacturing of Pharma Intermediate and APIs in accordance with various domestic and international standards, the Company has recently started undertaking custom manufacturing services for complex or novel chemical compounds
  • The Company started commercial production of Pharma Intermediate and API in 2018
  • It work out manufacturing activities at Rajkot, Gujarat, which comprise of two separate manufacturing blocks for manufacturing of Pharmaceutical Intermediate and APIs respectively with an aggregate installed production capacity of 400 MTPA
  • The Company launched the Initial Public Offering of 1,33,00,000 equity shares having the face value of Rs 10, by raising funds aggregating to Rs 121
  • 03 Cr via fresh issue on 29 August, 2025

Research Calls

Research Calls
Locked Access

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

Technical Indicators

RSI45.17
SMA 2025.93
SMA 5026.61
SMA 10020.85
SMA 20017.01
SMA 1026.23
MACD_12_26_Days-0.16
EMA10Day25.84
EMA20Day26.11
EMA50Day25.00
MACD_12_26_9_Days-0.22
EMA100Day22.22
EMA200Day19.00

Pivot Points

Volume Analysis

Delivery
Total Volume

Growth Rate

Revenue Growth42.96%
ROE18.73%
EBITDA Margin27.78%

All figures in ₹ Crores

Indicators20262025
Revenue
171.97
120.29
Interest
3.74
3.72
Expenses
124.45
88.08
Financing Profit
47.77
32.38
Financing Margin %
28%
27%
Other Income
0.26
0.17
Depreciation
1.52
1.77
Profit before tax
42.51
26.89
Tax %
32%
24%
Net Profit
29.09
20.52
EPS in Rs
6.11
6.37
Show % Change
ShareHolding
📊

No Information Available

No shareholding data available at this time.

📊

No Data Available

No Block Deals data available for this company.

News

📊

No Information Available

No news available for this company.
Record Date
Corporate Action
Information
Announcement Day
05 Sept 2026
AGM
AGM
17 Aug 2026
24 Apr 2026
Stock Split (1:5)
Face Value Change from 10 To 2
06 Mar 2026
24 Apr 2026
Bonus Issue (1:1)
1:1 Bonus issue of Equity Shares
10 Apr 2026

Peers

LTP(₹)
Market Cap(₹ Cr.)
P/E Ratio(Ratio)
P/B Ratio(Ratio)
Cash Earnings(Ratio)
Debt to Equity(Ratio)
Net Profit Ratio(%)
25
1,336
38
5
35
0
16.92%
1,885
4,52,299
37
5
30
0
19.78%
11,200
2,97,325
87
17
76
0
24.32%
4,699
1,78,727
82
10
44
1
11.09%
2,295
1,24,002
93
20
68
1
13.06%
1,195
1,19,207
26
4
18
0
9.82%
1,391
1,16,145
41
3
24
0
12.34%
1,415
1,14,312
37
3
26
0
9.92%
2,660
1,09,870
47
6
34
0
13.57%
1,795
1,03,298
25
3
17
0
10.41%
Showing 10 of 140 Results

Frequently Asked Questions

What is Share Price of Anlon Healthcare Ltd?

The current share price of Anlon Healthcare Ltd (Anlon Healthcare) is ₹25.17. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the P/E Ratio of Anlon Healthcare Ltd?

The Price-to-Earnings (P/E) ratio of Anlon Healthcare Ltd is 37.20. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.

What is the 52-week high and low of Anlon Healthcare Ltd?

Anlon Healthcare Ltd has a 52-week high of ₹37.24 and a 52-week low of ₹10.37. This range shows the stock's price volatility over the past year.

What is the Dividend Yield of Anlon Healthcare Ltd?

Anlon Healthcare Ltd offers a dividend yield of 0.00%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.

What is the EPS of Anlon Healthcare Ltd?

The Earnings Per Share (EPS) of Anlon Healthcare Ltd is ₹0.67. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.

What is the ROE of Anlon Healthcare Ltd?

Anlon Healthcare Ltd has a Return on Equity (ROE) of 19.17%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

mobile

Ready to invest smarter?
Download the app today.

GET IT ON

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

DOWNLOAD ON THE

App Store

4.2